Patents by Inventor Kirsten Timms

Kirsten Timms has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR DETERMING CANCER SUSCEPTIBILITY
    Publication number: 20130029926
    Abstract: The invention generally relates to a molecular classification of disease and particularly to molecular markers for cancer susceptibility and methods of use thereof. More specifically, the invention relates to the determination, screening, or classification of an individual's genetic risk for breast and ovarian cancer susceptibility.
    Type: Application
    Filed: November 5, 2010
    Publication date: January 31, 2013
    Applicant: Myriad Genetics, Inc.
    Inventors: Kirsten Timms, Jennifer Potter, Jerry Lanchbury
  • CANCER DETECTION MARKERS
    Publication number: 20120309018
    Abstract: Methods and compositions involving molecular markers for the detection and characterization of cancer in a patient are provided.
    Type: Application
    Filed: June 6, 2011
    Publication date: December 6, 2012
    Applicant: Myriad Genetics, Incorporated
    Inventors: Mark Skolnick, Jerry Lanchbury, Kirsten Timms, Chris Neff, Ryan Hoff, Hubert Wang, Susanne Wagner, Zaina Sangale
  • METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
    Publication number: 20120015050
    Abstract: This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.
    Type: Application
    Filed: June 20, 2011
    Publication date: January 19, 2012
    Applicant: Myriad Genetics, Incorporated
    Inventors: Victor Abkevich, Alexander Gutin, Kirsten Timms, Jerry Lanchbury
  • Depression-related gene
    Patent number: 7794933
    Abstract: The invention relate to the discovery of a depression associated AKAP9 predisposing variant. The invention provides for detecting the variant. The invention also provides methods for screening for antidepressants based on modulating AKAP9 mediated signaling.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: September 14, 2010
    Assignee: Myriad Genetics, Inc.
    Inventors: Jerry Lanchbury, Alexander Gutin, Kirsten Timms, Andrey Zharkikh
  • Gene copy number profiling
    Patent number: 7662566
    Abstract: The invention relates to copy number profile analysis. Specifically, copy number profile analysis is used to determine whether two or more separate tumors in a single individual are derived from a common source.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: February 16, 2010
    Assignee: Myriad Genetics, Inc.
    Inventors: Kirsten Timms, Alexander Gutin, Victor Abkevich, Jerry Lanchbury, Julie A. DeLoia, Alfred Guirguis, Esther Elishaev
  • GENE COPY NUMBER PROFILING
    Publication number: 20090029362
    Abstract: The invention relates to copy number profile analysis. Specifically, copy number profile analysis is used to determine whether two or more separate tumors in a single individual are derived from a common source.
    Type: Application
    Filed: November 21, 2007
    Publication date: January 29, 2009
    Applicants: Myriad Genetics, Incorporated, Magee-Womens Health Corporation
    Inventors: Kirsten Timms, Alexander Gutin, Victor Abkevich, Jerry Lanchbury, Julie A. DeLoia, Alfred Guirguis, Esther Elishaev
  • Gene variants and use thereof
    Publication number: 20070082347
    Abstract: Variants in TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 and AMFR genes are disclosed which are useful as biomarkers for predicting the TLK1, WARS2, ARTS2, MSR, AKAP9, DNAJD1, GOLPH4, RABEP1, TAP2, NARG2, DDX58, CD39, FKBP1a, SRI, XRRA1, IRF5 or AMFR gene expression level and the biological functions associated thereof.
    Type: Application
    Filed: June 8, 2006
    Publication date: April 12, 2007
    Applicant: Myriad Genetics, Incorporated
    Inventors: Jerry Lanchbury, Alexander Gutin, Andrey Zharkikh, Julia Reid, Kirsten Timms, Susanne Wagner, Ann-Marie Woodland